“We’re excited to bring this program into DesignMedix, because it expands our product pipeline with novel drug candidates aligned with our strength of bringing early-stage, small-molecule, anti-infectives into the clinic,” said Sandra Shotwell, Ph.D., DesignMedix CEO. “It also expands the types of infections we’re able to address.”
The lead indication for the new project will focus on Trichomonas vaginalis, the most common non-viral sexually transmitted disease, with 200 million cases worldwide each year.
“Emerging resistance to current drugs is a concern. Infection can have significant implications for women’s health, such as increased preterm birth rates, cervical cancer, and infertility. Most troubling of all, infection appears to increase susceptibility to HIV infection,” added Shotwell.
The company expects that the new program will have a broad impact on other infections that will significantly expand the potential of these compounds in the clinic.
About DesignMedix, Inc.
DesignMedix, Inc. was founded in 2008 to develop small molecule drugs to overcome drug resistance in treating infectious diseases. The company’s lead drug candidate is being prepared for clinical trials for malaria. For more information please visit:
February 22, 2016